Objective: This study aimed to evaluate the feasibility of completing a parallel-group randomized controlled trial to compare usual follow-up care for women who have completed treatment of gynecological cancer against a nurse-led telephone intervention, known as Optimal Personalised Care After TreatmentVGynaecological. Methods: The unblinded trial aimed to recruit patients who had completed treatment of cervical, endometrial, epithelial ovarian, or vulval cancer within the previous 3 months at 3 North Wales hospitals. We randomized participants to either usual hospital-based follow-up or specialist nurseYled telephone education, empowerment, and structured needs assessment follow-up. The primary outcomes assessed the feasibility of running a larger trial including patient eligibility, recruitment and retention rates, and outcome measure completion. Secondary outcomes were generic and health-related quality of life and a patient self-report health service use (Client Service Receipt Inventory) data collected at 3 time points (baseline, 3 months, and 6 months).
T
here are approximately 21,000 new cases of gynecological cancers each year in the United Kingdom, and 1 in 5 female cancer patients have a gynecological cancer 1 (Cancer Research UK 2014). In Wales, more than 1000 women are diagnosed as having gynecological cancers each year, 2 and in North Wales, where the feasibility study took place, more than 200 gynecological cancers were newly diagnosed in 2014. 3 The follow-up care currently provided after treatment of gynecological cancer is underpinned by a largely retrospective evidence base. Furthermore, there are no guidelines from the National Institute for Health and Care Excellence as to what form or frequency of follow-up is appropriate in relation to either effective recurrence detection or the patient's well-being. The Society of Gynecologic Oncology recommends that there is a need for prospective research including cost-effectiveness calculations to help determine ideal follow-up care. 4 The most common practice is for the clinician to review a patient on a regular basis, in a hospital-based, outpatient clinic over a number of years, 5 with the aim of checking for local recurrence or distant metastasis. 6 However, there is no prospective evidence that the traditional method of follow-up identifies recurrences earlier or improves overall survival because most recurrences are symptomatic. 7Y10 Follow-up of women with gynecological cancer may, therefore, be accomplished using patient-reported outcome measures. 11 A few retrospective studies reported that survival was better when recurrent cervical or endometrial cancer was detected at routine follow-up rather than when symptoms develop 12Y14 ; however, most patients relapse with symptoms that would prompt reassessment even if the patient was not on routine review. There is also a worry that patients may wait for their next routine appointment to disclose symptoms; 15 thus possibly delaying detection and appropriate symptom management.
In terms of psychological morbidity, there is evidence that routine appointments can lead to high levels of anxiety during follow-up, 16 suggesting that the patient's psychosocial needs are not being met. Within the population of cancer patients, it has been shown that women have significantly higher levels of anxiety and depression compared with men, 17 and furthermore, one study reported that 29% of gynecological cancer patients report depressive symptoms. 18 Studies have identified that the least met needs of cancer outpatients typically include receiving more information on genetic issues, lifestyle changes, worries regarding spread or recurrences, and parking near the treatment centers. 19 Furthermore, some patients have requested alternative models for follow-up. 20 With the lack of evidence to support medical-led, hospital-based follow-up as an effective model for earlier detection of recurrence with improved outcome, and to address the anxiety associated with scheduled appointments, we propose an alternative approach. This is to provide nurse-led telephone follow-up care for patients after treatment (Optimal Personalised Care After TreatmentVGynaecological [OPCAT-G]). The long-term aim is to develop a national, multicenter, randomized study that will determine the effectiveness of this new approach in terms of health economics, quality of life (QoL), patient autonomy, and survival for patients who have had treatment of gynecological cancer. The current feasibility study is designed to determine the ability to conduct a large trial according to the suggested protocol.
MATERIALS AND METHODS
The feasibility of completing a randomized controlled trial (RCT) on nurse-led telephone follow-up in the gynecology cancer setting (OPCAT-G) has been assessed in terms of several specific objectives: eligibility, recruitment, and retention rates of patients to the trial, along with completion rates of outcome measures. Secondary aims were to gain details to inform the design of a future trial by completing a process evaluation, an exploratory analysis to evaluate effect sizes, and an exploratory cost consequence analysis.
This parallel-group randomized controlled feasibility trial compared OPCAT-G (intervention arm) with standard care (control arm). Participants were randomized, using dynamic allocation to balance for the numbers of each cancer type that occur in the recruited population, 21 on a 1:1 basis using site (3 hospital sites) and disease type (endometrial, ovarian, cervical, and vulva) as stratification variables. A full description of the trial design is detailed within the published protocol article. 22 Inclusion criteria for participation in the study were as follows:
i. the patient had completed treatment of cervical, endometrial, epithelial ovarian, or vulval cancer; ii. treatment had been completed within the last 3 months; and iii. in the view of the treating consultant, there was no need for continued hospital-based care.
The exclusion criteria were as follows:
i. previous treatment of sarcoma, germ cell tumor, borderline tumors, melanoma, or choriocarcinoma because follow-up schedule usually requires a series of tests; ii. a need for ongoing treatment; iii. a lack of capacity to give informed consent; and iv. an inability to take part in the trial (eg, severe learning/ mental disability, severe mental health or hearing problems, and not able to understand Welsh or English).
Patients were recruited from 3 hospitals in North Wales, United Kingdom, by the research nurse (RN) and clinical nurse specialists (CNSs). Potential patients were given a participant information sheet at their end of treatment visit and had until their first follow-up appointment to consider the study (on average 56 days apart) where they gave consent and completed the baseline questionnaire before being randomized.
The participants, RN and CNSs, and trial management were unblinded during this trial. All other members of the team (including the research officer, chief investigators, and the trial statistician) were blinded. The blinded members would have had access to a coded breakdown of treatment group assignments, which was only broken after analysis.
Patients randomized to standard care continued to have their hospital-based, consultant-led medical reviews at 3 and 6 months after baseline and were followed up according to an agreed protocol with the regional gynecological cancer multidisciplinary team that represented current practice.
Patients randomized to the OPCAT-G intervention arm received an information booklet at baseline, which included information on i. patterns of relapse, possible warning symptoms, and how to respond to these; ii. possible long-term physical and psychological side effects of treatment and how these can be managed; iii. how patients could contact the clinical team if they have concerns or symptoms; iv. treatment, diagnosis, and disease-specific information; and v. needs assessment measures made up from the Macmillan Concerns Checklist, 23 19 and the Distress Thermometer. 24 These participants did not attend the hospital for their follow-up appointments but instead received a scheduled nurse-led telephone follow-up, firstly within 4 weeks of randomization and again 6 months after baseline. Patients were asked to complete the needs assessment measures before each scheduled telephone call to inform a structured discussion with the CNS. Any issues identified in these calls were referred to the most appropriate source of help. Additional telephone calls could be instigated at any time by the patient, where her completed needs assessments would be discussed as with scheduled calls.
A process evaluation was included to reflect upon the recruitment strategy of the trial and explain any differences present between the recruiting sites. Assessment of key variables that influenced recruitment to this feasibility trial should facilitate improved recruitment into a future RCT. All of the nurses (3 CNSs and 1 RN) who were part of the trial took part in process evaluation interviews after the follow-up period was completed. The interviews were either face-to-face or by telephone, lasted 30 to 45 minutes (see Appendix 1, http://links. lww.com/IGC/A593 for the interview schedule), and were recorded, transcribed, and checked afterward.
To evaluate the appropriateness of measures and potentially identify a primary outcome for a future RCT, the following outcome measures were collected. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)YCore 30 item (C30), 25 EuroQol 5 Dimension 3-level version of a measure of healthrelated quality of life (EQ-5D-3L), 26 ICEpop CAPability measure for Adults (ICECAP-A), 27 and a Client Service Receipt Inventory. 28, 29 All outcomes were aiming to assess the QoL and well-being of the participants (see Appendix 2, http://links.lww. com/IGC/A593 for further details). All of these were completed at 3 time points: baseline, 3 months, and 6 months after baseline. In addition, patient demographics relating to their characteristics, cancer disease type, and treatment were collected at baseline.
The sample size was estimated based on the assumption of screening 150 patients during a 6-month recruitment period, with approximately 30% of these being ineligible and 50% acceptance into the trial. This resulted in a provisional estimate of recruiting 50 patients to the trial.
Calculating effect sizes for the relevant outcome measures was completed using analysis of covariance (ANCOVA) models on the 6-month follow-up data adjusting for the participant's baseline scores, site, and disease type (stratification variables). Normality of the outcomes has been evaluated to ensure appropriate use of this analysis. All statistical analyses were undertaken using IMB SPSS Statistics 22 30 and completed on an intention-to-treat basis. All analyses relating to health economics were undertaken using Microsoft Excel 2010 and IBM SPSS Statistics 22. 
RESULTS
Fifty-eight women were screened to take part in the study during a period of 6 months between September 2015 and February 2016. Those deemed eligible to take part in the study accounted for 76% of the screened population (44 patients), with the main reason for ineligibility being that the patient required ongoing hospital care (64%). Of the 44 eligible women, 24 consented to take part in the study, giving a recruitment rate of 55%. The main reason for nonrecruitment was that patients did not want to be randomized (70%) and the main basis for this was due to wanting to see a doctor for their follow-up (10/14 patients). Only 1 patient was lost to followup during the study, giving a retention rate of 96%. The CONSORT flowchart in Figure 1 provides a further breakdown of these data.
The desired thresholds defined in the protocol and statistical analysis plan a priori were at least 50% eligibility, recruitment, and retention rates. These criteria have been satisfied.
All 3 sites within the study were successful at recruiting participants, but to varying degrees. The results of the process evaluation showed that the differences in recruitment success at the 3 trial sites were mainly due to the lack of early CNS involvement in the feasibility trial, lack of sufficient training, and a lack of research network support due to the limited funding available to the feasibility trial. A CNS response to poor recruitment was as follows:
''I do personally feel I should have been involved a lot sooner. And I know they didn't want to involve too many people but actually I we were quite crucial in it all, and especially because of local knowledge, so I did feel I we didn't have enough preparation for it and then there was a lot of pressure to get I recruitment up I.''
Research network support in terms of RN time and additional training would have increased the CNSs' understanding of the protocol.
The participants who were recruited into the study had a mean age of 59.8 years and had received their initial diagnosis FIGURE 1. CONSORT diagram for the TOPCAT-G feasibility trial. a little over 5 months (mean, 159 days) before randomization. Eligibility criteria stipulated at baseline were that the participant must be within 3 months of her last treatment and this was confirmed by the mean of 84 days after treatment found in the study sample. One person was 109 days from her end of treatment because of unforeseen appointment rescheduling, but with the chief investigator's agreement, this person was included within the study. Most participants (71%) had treatment of endometrial cancer (21% ovarian, 8% cervical, none had vulval carcinoma). All patients received surgery as part of their treatment, 46% combined this with either chemotherapy or radiotherapy (see Table 1 for further details).
Completion rates of the QoL and well-being measures were evaluated based on the final scores for the measures collected within the study. Four outcomes (nausea and vomiting subscale, appetite loss subscale, diarrhoea subscale, and EQ-5D-3L index) had one data point missing at baseline, giving a minimum completion at the time point of 96%. All outcomes during the 3-and 6-month follow-up achieved completion rates of 100%.
Assumptions of normality were met based on scrutiny of distributions of composite variables; single-or dual-item variables are treated as categorical. The appropriate descriptive statistics (means and SD for normally distributed subscales and the modal class for the remaining subscales) of the EORTC-QLQ-C30 are presented in Table 2 . Differences were noted at baseline between the 2 treatment allocations on several outcome measures outlining the importance of baseline adjustments where possible. For all subscales, the OPCAT-G intervention had equal or better scores at 6-month follow-up compared with the standard care arm of the study. The ANCOVA models on the 4 appropriate subscales have evaluated all effect sizes in a positive direction for the OPCAT-G intervention ( Table 2 ). The largest effect was identified on the physical functioning subscale, but the QoL and fatigue subscales also identified changes of 4 points. All effects have large confidence intervals (CIs) because of the small sample size and so should be taken as indicative only.
For the purposes of the economic analysis, this feasibility took a National Health Service (NHS) and voluntary sector perspective. An exploratory cost consequences analysis was conducted on the participants who had complete cost and outcome data (n = 21: 10 in the intervention arm, 11 in the control arm). The frequency of contacts with primary and secondary care health services and other cancer services used at 6 months after baseline can be found in Supplementary Material Table 1 , http:// links.lww.com/IGC/A593. Results show that there is no significant difference between the 2 groups in the frequency of contacts with primary care and other cancer services. For secondary care, no significant difference between groups was shown for all secondary care service contacts, except telephone contacts with the CNSs in which the OPCAT-G intervention group had, on average, higher usage (mean frequency, 1.70) than did the standard care group (mean frequency, 0.27). Table 3 shows intervention delivery cost details for the OPCAT-G intervention and standard care. Results show that mean intervention cost per patient for delivering the OPCAT-G intervention and standard care was U76.02 and U52.99 per patient, respectively, a difference of U23.03. Table 4 shows mean costs of all contacts with NHS primary and secondary care services and other cancer services by participants in the OPCAT-G intervention and standard care groups over the 6-month follow-up period. These included primary care consultations, secondary care consultations, and other cancer services (eg, voluntary sector support). Results show that the mean (SD) total cost per patient was U388.84 (U320.11) for the OPCAT-G intervention group and U415.44 (U329.08) for the standard care group over the 6-month follow up period. The difference in mean total cost between the 2 groups was jU26.60 (bootstrapped 95% CI, jU290.37 to U240.42). Although this difference is not statistically significant, the mean total costs of service use were lower in the OPCAT-G intervention group. Table 5 shows that participants in the OPCAT-G intervention group had, on average, a smaller QoL years (QALY) gain compared with participants in the standard care group, with a mean difference of j0.06 QALYs (bootstrapped 95% CI, j0.18 to 0.05); this difference was not statistically significant. Two adverse events were reported during the trial, one relapse and one pulmonary embolism, neither were deemed to be trial related and both continued in the trial.
DISCUSSION
We have demonstrated the feasibility of Trial of Optimal Personalised Care After TreatmentYGynaecological Cancer (TOPCAT-G) as a trial in terms of acceptable eligibility, recruitment, and retention rates related to rates defined a priori. In addition, all outcome measures were completed to a high standard and there is no concern about including these in a future definitive RCT. The trial had the potential to include a range of difference tumor types; however, the sample recruited was highly biased toward early-stage endometrial cancer patients. There were no vulval cancer patients recruited during the limited recruitment window. A future study needs to ensure a sufficiently representative population of gynecological patients to enhance the generalizability of findings. The process evaluation showed that involvement of the local CNSs is important for their recruitment with training and regular contact including site visits from the central TOPCAT-G research team members. There were implications for the CNSs in terms of screening clinics to increase the number of patients approached and then in terms of conducting the actual intervention, as telephone reviews had not previously been conducted at 2 of the sites before the trial. The study did have an impact on the CNS work, and they felt that they had not been consulted about it soon enough. These issues could have been resolved with a formal ''training day'' explaining the aims and objectives as well as the work required rather than an informal discussion. It is essential for those involved to understand the rationale of why the study is being conducted. For the full trial, sites will need to go through a feasibility check to open and see if they have the resources to take part in terms of network support and CNS involvement. The CNSs would need to feel at ease conducting the intervention and would need to be consulted and involved early on in assessing suitability as a site for trial recruitment.
The current study may have been limited by requiring recruitment within 3 months after the end of treatment. A participant was included from outside the recruitment window. With appointment cancellations and changes, this proved a strain for the nurses to ensure this time window was met. From a clinical point of view, this timeline was not essential. It is, however, important that treatment be completed in order for the ''follow-up phase'' of care to begin, and so recruitment should be as soon as is reasonable after completing treatment to eliminate any treatment-related problems experienced at this time requiring a specialist's help. 5 This recruitment window will be reconsidered within a full trial and the most appropriate time limits allocated to the inclusion criteria.
One major operational issue for the study was finding appropriate dedicated time for each of the CNSs to complete their telephone follow-up interviews with the participants. Gaining information on issues such as this is a vital part of shaping the design of a future RCT. Each telephone follow-up took on average 34.7 minutes for the CNSs to complete.
The mean overall total time spent by CNSs for delivering the nurse-led intervention (95.2 minutes) was shown to be higher than the average overall total time spent by outpatient doctors for delivering the routine clinic follow-up (23.6 minutes). This difference was perhaps due to all time spent by outpatient doctors not being collected in this feasibility trial, leading to a possible underestimation of outpatient doctor time. Additional time was required for doctors looking through patients' hospital notes before and after seeing patients. For consistency and accuracy, the preparation, contact time, and subsequent time spent by outpatient doctors should be recorded within a future definitive RCT. Despite this, the exploratory cost consequences analysis results demonstrate that the intervention group had a mean total service use cost of U27 per patient (bootstrapped 95% CI, jU290 to U240) lower than did the standard care group.
In conclusion, the feasibility trial demonstrated that the study protocol had satisfactory eligibility, recruitment, and retention rates as well as satisfactory outcome measure completion. Analyses of outcome measures indicated positive changes in QoL and well-being within the OPCAT-G group; exploratory cost consequence analysis indicated that the nurse-led intervention had a mean total service use cost of U27 per patient lower than did the standard care group. 
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